ZIVO Bioscience, Inc. (ZIVOW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZIVO Bioscience, Inc. (ZIVOW) trades at $0.044 with AI Score 59/100 (Grade B). ZIVO Bioscience, Inc. is a biotechnology company focused on developing and commercializing bioactive ingredients derived from proprietary algae cultures. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ZIVOW: ZIVOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZIVOW against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ZIVOW: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ZIVO Bioscience, Inc. (ZIVOW) Healthcare & Pipeline Overview
ZIVO Bioscience, Inc. operates in the biotech and agtech sectors, focusing on natural bioactive ingredients from algae. With a portfolio of patents and proprietary strains, the company targets animal and human health markets, differentiating itself through unique production and cultivation techniques for specialized applications.
What Is the Investment Thesis for ZIVOW?
ZIVO Bioscience presents a speculative investment opportunity in the early-stage biotechnology sector. The company's focus on algae-derived bioactive ingredients for animal and human health offers potential in the growing market for natural health solutions. A key value driver is the successful licensing and commercialization of its proprietary ingredients. The company's gross margin of 31.7% indicates some pricing power. Upcoming catalysts include potential partnerships with manufacturers and the advancement of its product pipeline. However, the company's negative profit margin of -4059.7% and small market capitalization of $0.00B highlight significant financial risks. The company's small size, with only 7 employees, also creates operational risks. Investors should carefully consider the high-risk, high-reward nature of this investment.
Based on FMP financials and quantitative analysis
ZIVOW Key Highlights
- Gross Margin of 31.7% indicates potential pricing power in its niche market.
- Focus on natural bioactive ingredients aligns with growing consumer demand for natural health solutions.
- Intellectual property portfolio provides a degree of competitive advantage.
- Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also high risk.
- Negative Profit Margin of -4059.7% reflects the company's early stage and ongoing investment in research and development.
Who Are ZIVOW's Competitors?
ZIVOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZIVOW's Key Strengths?
- Proprietary algae strains and cultivation techniques.
- Focus on natural and sustainable ingredients.
- Intellectual property portfolio.
- Potential for growth in the animal and human health markets.
What Are ZIVOW's Weaknesses?
- Small size and limited resources.
- Negative profit margin and reliance on external funding.
- Limited commercialization experience.
- Dependence on a small number of key products and customers.
What Could Drive ZIVOW Stock Higher?
- Announcement of new partnerships or licensing agreements.
- Publication of positive results from clinical trials or research studies.
- Regulatory approvals for new products or indications.
- Expansion of the company's intellectual property portfolio.
- Increasing demand for natural health solutions.
What Are the Key Risks for ZIVOW?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger and more established companies.
- Regulatory hurdles and approval processes.
- Fluctuations in raw material prices.
- Dependence on external funding.
- Limited commercialization experience.
What Are the Growth Opportunities for ZIVOW?
- Expansion into Human Health Markets: ZIVO has the opportunity to expand its product offerings into the human health market, targeting dietary supplements, medical foods, and other applications. The global dietary supplements market is projected to reach $278 billion by 2028, offering a substantial market opportunity for ZIVO's bioactive ingredients. Successful clinical trials and regulatory approvals will be critical for this expansion.
- Strategic Partnerships and Licensing Agreements: ZIVO can accelerate its growth by forming strategic partnerships with established manufacturers and distributors in the animal and human health industries. Licensing agreements can provide a steady stream of revenue and expand the reach of ZIVO's products. Identifying and securing partnerships with companies that have strong market access and distribution networks is crucial.
- Development of Novel Bioactive Ingredients: Continued investment in research and development is essential for ZIVO to develop novel bioactive ingredients with unique health benefits. This will strengthen its intellectual property portfolio and differentiate its products from competitors. Focus on identifying and validating new algal strains and bioactive molecules with potential applications in various health areas.
- Geographic Expansion: ZIVO can expand its geographic reach by targeting new markets in Asia, Europe, and other regions. The global demand for natural health solutions is growing rapidly in these markets, presenting significant opportunities for ZIVO's products. Adapting its products and marketing strategies to meet the specific needs and preferences of each market will be essential.
- Focus on Sustainability and Traceability: Consumers are increasingly demanding sustainable and traceable products. ZIVO can capitalize on this trend by emphasizing the sustainable sourcing and production of its algal-derived ingredients. Implementing transparent and traceable supply chains will enhance its brand reputation and attract environmentally conscious customers.
What Opportunities Does ZIVOW Have?
- Expansion into new markets and product categories.
- Strategic partnerships and licensing agreements.
- Increasing demand for natural health solutions.
- Development of novel bioactive ingredients.
What Threats Does ZIVOW Face?
- Competition from larger and more established companies.
- Regulatory hurdles and approval processes.
- Fluctuations in raw material prices.
- Potential for product liability claims.
What Are ZIVOW's Competitive Advantages?
- Proprietary algae strains and cultivation techniques.
- Patented extraction processes and bioactive ingredients.
- Intellectual property portfolio protecting its innovations.
- Focus on natural and sustainable ingredients, aligning with consumer trends.
What Does ZIVOW Do?
ZIVO Bioscience, Inc., established in 2014 (formerly Health Enhancement Products, Inc.), is a research and development company focused on discovering, developing, and commercializing natural bioactive ingredients derived from its proprietary algae cultures. Headquartered in Bloomfield Hills, Michigan, the company operates within the biotech and agtech sectors, leveraging its intellectual property portfolio to create value. ZIVO's core business revolves around licensing and selling these ingredients to manufacturers in the animal, human, dietary supplement, and medical food industries. The company's intellectual property includes proprietary algal and bacterial strains, biologically active molecules and complexes, and patented or patent-pending inventions. These innovations are applied to develop products targeting various health indications. ZIVO's product pipeline addresses areas such as poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health and anti-aging. ZIVO Bioscience aims to establish itself as a key supplier of novel bioactive ingredients, capitalizing on the growing demand for natural and sustainable solutions in the health and wellness markets. The company's research and development efforts are geared towards expanding its product portfolio and strengthening its competitive position through continued innovation and intellectual property protection.
What Products and Services Does ZIVOW Offer?
- Develops proprietary algae cultures.
- Extracts natural bioactive ingredients from algae.
- Licenses and sells these ingredients to manufacturers.
- Targets the animal health market with products for poultry, bovine, and canine health.
- Targets the human health market with products for immune modification and skin health.
- Focuses on research and development to expand its product portfolio.
- Protects its innovations through patents and intellectual property.
How Does ZIVOW Make Money?
- Develops and patents proprietary algae strains and extraction processes.
- Cultivates algae and extracts bioactive ingredients.
- Licenses or sells these ingredients to manufacturers of animal and human health products.
- Generates revenue through licensing fees and product sales.
What Industry Does ZIVOW Operate In?
ZIVO Bioscience operates within the biotechnology industry, specifically focusing on the development of bioactive ingredients for the animal and human health markets. This industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The market for natural health solutions is experiencing significant growth, driven by increasing consumer awareness and demand for sustainable and healthy products. ZIVO competes with other biotechnology companies, as well as larger players in the animal and human health sectors. Companies like AVGR, CWBR, CYTO, NAYA, and NBSE also operate in related spaces.
Who Are ZIVOW's Key Customers?
- Animal health product manufacturers.
- Human dietary supplement manufacturers.
- Medical food manufacturers.
- Companies seeking natural bioactive ingredients for their products.
ROE 426%Key Financial Metrics
Return on equity for ZIVO Bioscience, Inc. stands at 426.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.
ZIVO Bioscience, Inc. (ZIVOW) Valuation Context
Relative to its peer group, ZIVOW's quantitative score of 59/100 is below the peer average of 73/100.
Company Profile
ZIVO Bioscience, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bloomfield Hills, US. The company is led by CEO John Bernard Payne. ZIVOW has traded publicly since 2003.
F-Score 3/9Financial Health
ZIVO Bioscience, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ZIVOW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary algae strains and cultivation techniques.
- Focus on natural and sustainable ingredients.
- Intellectual property portfolio.
- Potential for growth in the animal and human health markets.
Bear Case
- Small size and limited resources.
- Negative profit margin and reliance on external funding.
- Limited commercialization experience.
- Dependence on a small number of key products and customers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ZIVOW Latest News
No recent news available for ZIVOW.
ZIVOW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZIVOW.
Price Targets
Wall Street price target analysis for ZIVOW.
ZIVOW MoonshotScore
What does this score mean?
The MoonshotScore rates ZIVOW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Bernard Payne
CEO
John Bernard Payne serves as the CEO of ZIVO Bioscience, Inc. His background includes experience in managing and growing companies in the biotechnology and related sectors. He has a track record of leading teams and driving innovation. Payne's expertise encompasses strategic planning, business development, and financial management. His leadership is focused on advancing ZIVO's research and development efforts and commercializing its proprietary technologies.
Track Record: Under John Bernard Payne's leadership, ZIVO Bioscience has focused on expanding its intellectual property portfolio and advancing its product pipeline. Key milestones include securing patents for its proprietary algae strains and bioactive ingredients, as well as establishing partnerships for product development and commercialization. Payne has also overseen the company's efforts to raise capital and build a strong team.
What Investors Ask About ZIVO Bioscience, Inc. (ZIVOW) — Healthcare
What does the AI Score mean for ZIVOW?
ZIVOW holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. ZIVO Bioscience, Inc. is a biotechnology company focused on developing and commercializing bioactive ingredients derived from proprietary algae cultures. Their products target animal and human …
What does ZIVO Bioscience, Inc. do?
ZIVO Bioscience, Inc. is a biotechnology company focused on developing and commercializing natural bioactive ingredients derived from its proprietary algae cultures. The company operates in the animal and human health markets, licensing and selling its ingredients to manufacturers of dietary supplements, medical foods, and other health products. ZIVO's core business revolves around its intellectual property, including proprietary algal strains, extraction processes, and bioactive molecules.
What do analysts say about ZIVOW stock?
As of March 17, 2026, there is no readily available analyst coverage for ZIVOW stock due to its small market capitalization and early stage of development. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics to consider include revenue growth, gross margin, and cash flow.
What are the main risks for ZIVOW?
ZIVO Bioscience, Inc. faces several risks, including competition from larger and more established companies, regulatory hurdles and approval processes, fluctuations in raw material prices, dependence on external funding, and limited commercialization experience. The company's small size and negative profit margin also pose significant financial risks. Investors should carefully consider these risks before investing in ZIVOW stock.
What is ZIVO Bioscience, Inc.'s drug pipeline status?
ZIVO Bioscience, Inc. is primarily focused on developing bioactive ingredients for animal and human health, rather than traditional pharmaceuticals. Its product pipeline includes ingredients targeting poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health and anti-aging. The company's strategy involves licensing these ingredients to manufacturers, rather than developing and marketing its own finished products.
How does ZIVO Bioscience, Inc. manage patent expiration risks?
As ZIVO Bioscience, Inc. is focused on bioactive ingredients rather than traditional pharmaceuticals, the company's patent strategy revolves around protecting its proprietary algal strains, extraction processes, and bioactive molecules. While the company does not face the same patent cliff risks as pharmaceutical companies, it must continuously innovate and develop new intellectual property to maintain its competitive advantage.
What are the key factors to evaluate for ZIVOW?
ZIVO Bioscience, Inc. (ZIVOW) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does ZIVOW data refresh on this page?
ZIVOW's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZIVOW's recent stock price performance?
ZIVO Bioscience, Inc. (ZIVOW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary algae strains and cultivation techniques. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.
- The company's small size and limited financial information may impact the accuracy of the analysis.